Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0E6S3)

Drug Name

Suvorexant Drug Info

Synonyms

Suvorexant; 1030377-33-3; MK-4305; BELSOMRA; MK 4305; MK4305; UNII-081L192FO9; Suvorexant (MK-4305); [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone; (R)-(4-(5-Chlorobenzo[d]oxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone; CHEMBL1083659; CHEBI:82698; 081L192FO9; C23H23ClN6O2; ((7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Approved	[1]

Cross-matching ID

PubChem CID: 24965990
ChEBI ID: CHEBI:82698
CAS Number: CAS 1030377-33-3
TTD Drug ID: DM0E6S3
VARIDT Drug ID: DR00487
INTEDE Drug ID: DR1521
ACDINA Drug ID: D00647

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Orexin receptor type 2 (HCRTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-3697	DM347TQ	Insomnia	7A00-7A0Z	Phase 2	[4]
MIN-202	DMZFW8V	Major depressive disorder	6A70.3	Phase 2	[5]
TAK-861	DMLGEQ7	Narcolepsy type 1	7A20.0	Phase 2	[6]
TAK-925	DM7N4H9	Narcolepsy	7A20	Phase 1	[7]
1,2-diamino cyclopentane-based derivative 25	DMEW0AT	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 5	DMCP15K	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 20	DM9PHIK	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 15	DMBY65W	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 13	DM10UX4	N. A.	N. A.	Patented	[8]
1,2-diamino cyclopentane-based derivative 9	DM7I8ZV	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[9]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[10]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[11]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[12]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[13]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[15]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[16]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[10]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Orexin receptor type 2 (HCRTR2)	TT9N02I	OX2R_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)^{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[3]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2890).
2	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3	Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat. 2016 Feb 25;12:491-5.
4	Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
7	Molecular mechanism of the wake-promoting agent TAK-925. Nat Commun. 2022 May 25;13(1):2902.
8	Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15.
9	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
10	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
11	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
12	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
13	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
15	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
16	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.